PMV Consumer (PMVC) to Liquidate Trust, But Continue Trading
by Nicholas Alan Clayton on 2022-11-25 at 2:31pm

PMV Consumer (OTC PINK:PMVC) announced that it is redeeming all non-insider public shares for approximately $10.09 per share, but it will not be dissolving just yet.

The SPAC is set to provide written redemption notices to each shareholder and trust proceeds are to be distributed within 30 days of these notices. PMV Consumer will then remain listed on the OTC Pink Sheets with the 3,000,000 Class A shares owned by its sponsor.

Post-redemption, the SPAC plans to file a Form 15 to remove its filing requirements and “continue to pursue a wide range of business opportunities operating as a blank check shell company”, according to its press release.

Alternatively, a holder may elect to receive shares of Class C Common Stock issued on a one-for-one basis for the number of Class A Shares redeemed from such holder. Public shareholders that want to stick along for the ride may also elect to receive a pro rata share of 200,000 Class C shares. The pro rata share of the Class C Common Stock will be calculated by dividing the number of Class A Shares redeemed from a holder by the total number of Class A Shares redeemed from all holders of Class A Shares that elect the Stock Election.

These Class C shares will also remain unlisted and so will function as a sort of mini-promote held by public shareholders if and until PMV Consumer completes a business combination down the road.

And, unlike many SPACs now liquidating in the final weeks of the year, PMV Consumer does have some tread left on its tires. In September, it extended its transaction deadline until September 21, 2023.

Although 88% shares were redeemed in connection with the vote, shareholders also approved a measure allowing PMV Consumer to increase its authorized stock from 86,000,000 to 120,000,000, which may give it more flexibility as a pink sheets acquisition vehicle.

This is an interesting third option for SPACs facing down deadlines over the next few months. Albeit, less grandiose than Bill Ackman’s SPARC concept. But, this nonetheless could be an approach that teams could toy with as a means of extending a SPAC’s life with the ability to opt-out and opt-in shareholders.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved